Neal E. Ready
Elite in Non-Small Cell Lung Cancer (NCSLC)
Check Dr. Neal E. Ready's experience treating your condition:
About Dr. Neal E. Ready

Neal Ready is an Oncologist in Durham, North Carolina. Ready has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NCSLC). He is also highly rated in 21 other conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Small Cell Lung Cancer (SCLC), Large-Cell Lung Carcinoma, and Gamma Knife Radiosurgery. He is licensed to treat patients in North Carolina. Ready is currently accepting new patients.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 12 clinical trials in the past 15 years. In particular, he has co-authored 43 articles and participated in 6 clinical trials in the study of Non-Small Cell Lung Cancer (NCSLC).


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Neal E. Ready it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
20 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
Vanderbilt University School Of Medicine, 1986
Internal Medicine in NC
Hospital Affiliations
Duke Regional Hospital
Duke University Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study
Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC).
Identification of a Gene Expression Signature Profile for Panitumumab Sensitivity in Untreated Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer
ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study
Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study
Sorafenib and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN):a Phase I B/II Trial
View 10 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors